Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1990 Mar 10;300(6725):655–659. doi: 10.1136/bmj.300.6725.655

Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

I C Macdougall 1, R D Hutton 1, I Cavill 1, G A Coles 1, J D Williams 1
PMCID: PMC1662415  PMID: 2322705

Abstract

Treatment with erythropoietin is highly effective and beneficial if given with care. In view of its cost, however, it is essential to exclude and treat other causes of anaemia before considering using this hormone. After treatment is started the important points for success are regular review of iron availability state combined with a slow correction of the anaemia. Failure of response requires a thorough search for a possible cause, which should be corrected before considering an increased dose of the hormone. Regular monitoring for potential complications, particularly a rise in blood pressure, is required.

Full text

PDF
655

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BAINTON D. F., FINCH C. A. THE DIAGNOSIS OF IRON DEFICIENCY ANEMIA. Am J Med. 1964 Jul;37:62–70. doi: 10.1016/0002-9343(64)90212-8. [DOI] [PubMed] [Google Scholar]
  2. Boelaert J. R., Schurgers M. L., Matthys E. G., Belpaire F. M., Daneels R. F., De Cre M. J., Bogaert M. G. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int. 1989;9(2):95–98. [PubMed] [Google Scholar]
  3. Bommer J., Alexiou C., Müller-Bühl U., Eifert J., Ritz E. Recombinant human erythropoietin therapy in haemodialysis patients--dose determination and clinical experience. Nephrol Dial Transplant. 1987;2(4):238–242. [PubMed] [Google Scholar]
  4. Bommer J., Ritz E., Weinreich T., Bommer G., Ziegler T. Subcutaneous erythropoietin. Lancet. 1988 Aug 13;2(8607):406–406. doi: 10.1016/s0140-6736(88)92886-3. [DOI] [PubMed] [Google Scholar]
  5. Caro J., Brown S., Miller O., Murray T., Erslev A. J. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med. 1979 Mar;93(3):449–458. [PubMed] [Google Scholar]
  6. Casati S., Passerini P., Campise M. R., Graziani G., Cesana B., Perisic M., Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J (Clin Res Ed) 1987 Oct 24;295(6605):1017–1020. doi: 10.1136/bmj.295.6605.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cook J. D., Skikne B. S., Lynch S. R., Reusser M. E. Estimates of iron sufficiency in the US population. Blood. 1986 Sep;68(3):726–731. [PubMed] [Google Scholar]
  8. De Paepe M. B., Schelstraete K. H., Ringoir S. M., Lameire N. H. Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease. Kidney Int. 1983 May;23(5):744–748. doi: 10.1038/ki.1983.88. [DOI] [PubMed] [Google Scholar]
  9. Eschbach J. W., Adamson J. W. Recombinant human erythropoietin: implications for nephrology. Am J Kidney Dis. 1988 Mar;11(3):203–209. doi: 10.1016/s0272-6386(88)80150-1. [DOI] [PubMed] [Google Scholar]
  10. Eschbach J. W., Downing M. R., Egrie J. C., Browne J. K., Adamson J. W. USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients. Contrib Nephrol. 1989;76:160–218. doi: 10.1159/000417892. [DOI] [PubMed] [Google Scholar]
  11. Eschbach J. W., Egrie J. C., Downing M. R., Browne J. K., Adamson J. W. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987 Jan 8;316(2):73–78. doi: 10.1056/NEJM198701083160203. [DOI] [PubMed] [Google Scholar]
  12. Eschbach J. W., Kelly M. R., Haley N. R., Abels R. I., Adamson J. W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med. 1989 Jul 20;321(3):158–163. doi: 10.1056/NEJM198907203210305. [DOI] [PubMed] [Google Scholar]
  13. Eschbach J. W. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989 Jan;35(1):134–148. doi: 10.1038/ki.1989.18. [DOI] [PubMed] [Google Scholar]
  14. Frenken L. A., Coppens P. J., Tiggeler R. G., Koene R. A. Intraperitoneal erythropoietin. Lancet. 1988 Dec 24;2(8626-8627):1495–1495. doi: 10.1016/s0140-6736(88)90975-0. [DOI] [PubMed] [Google Scholar]
  15. Granolleras C., Branger B., Beau M. C., Deschodt G., Alsabadani B., Shaldon S. Experience with daily self-administered subcutaneous erythropoietin. Contrib Nephrol. 1989;76:143–148. doi: 10.1159/000417890. [DOI] [PubMed] [Google Scholar]
  16. Kovacs J. A., Gill V., Swan J. C., Ognibene F., Shelhamer J., Parrillo J. E., Masur H. Prospective evaluation of a monoclonal antibody in diagnosis of Pneumocystis carinii pneumonia. Lancet. 1986 Jul 5;2(8497):1–3. doi: 10.1016/s0140-6736(86)92555-9. [DOI] [PubMed] [Google Scholar]
  17. Levin N. Management of blood pressure changes during recombinant human erythropoietin therapy. Semin Nephrol. 1989 Mar;9(1 Suppl 2):16–20. [PubMed] [Google Scholar]
  18. Lim V. S., DeGowin R. L., Zavala D., Kirchner P. T., Abels R., Perry P., Fangman J. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med. 1989 Jan 15;110(2):108–114. doi: 10.7326/0003-4819-110-2-108. [DOI] [PubMed] [Google Scholar]
  19. MacDougall I. C., Roberts D. E., Coles G. A., Williams J. D. Intraperitoneal erythropoietin. Lancet. 1989 Jun 17;1(8651):1389–1389. doi: 10.1016/s0140-6736(89)92833-x. [DOI] [PubMed] [Google Scholar]
  20. Macdougall I. C., Cavill I., Davies M. E., Hutton R. D., Coles G. A., Williams J. D. Subcutaneous recombinant erythropoietin in the treatment of renal anaemia in CAPD patients. Contrib Nephrol. 1989;76:219–226. doi: 10.1159/000417898. [DOI] [PubMed] [Google Scholar]
  21. Macdougall I. C., Hutton R. D., Cavill I., Coles G. A., Williams J. D. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989 Jul 15;299(6692):157–158. doi: 10.1136/bmj.299.6692.157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Macdougall I. C., Roberts D. E., Neubert P., Dharmasena A. D., Coles G. A., Williams J. D. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet. 1989 Feb 25;1(8635):425–427. doi: 10.1016/s0140-6736(89)90014-7. [DOI] [PubMed] [Google Scholar]
  23. Mayer G., Thum J., Cada E. M., Stummvoll H. K., Graf H. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int. 1988 Oct;34(4):525–528. doi: 10.1038/ki.1988.213. [DOI] [PubMed] [Google Scholar]
  24. McGonigle R. J., Husserl F., Wallin J. D., Fisher J. W. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int. 1984 Feb;25(2):430–436. doi: 10.1038/ki.1984.35. [DOI] [PubMed] [Google Scholar]
  25. Meytes D., Bogin E., Ma A., Dukes P. P., Massry S. G. Effect of parathyroid hormone on erythropoiesis. J Clin Invest. 1981 May;67(5):1263–1269. doi: 10.1172/JCI110154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Moia M., Mannucci P. M., Vizzotto L., Casati S., Cattaneo M., Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet. 1987 Nov 28;2(8570):1227–1229. doi: 10.1016/s0140-6736(87)91849-6. [DOI] [PubMed] [Google Scholar]
  27. Raine A. E. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet. 1988 Jan 16;1(8577):97–100. doi: 10.1016/s0140-6736(88)90293-0. [DOI] [PubMed] [Google Scholar]
  28. Schaefer R. M., Hörl W. H., Massry S. G. Treatment of renal anemia with recombinant human erythropoietin. Am J Nephrol. 1989;9(5):353–362. doi: 10.1159/000167996. [DOI] [PubMed] [Google Scholar]
  29. Schaefer R. M., Leschke M., Strauer B. E., Heidland A. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol. 1988;8(6):449–453. doi: 10.1159/000167652. [DOI] [PubMed] [Google Scholar]
  30. Stevens J. M., Strong C. A., Oliver D. O., Winearls C. G., Cotes P. M. Subcutaneous erythropoietin and peritoneal dialysis. Lancet. 1989 Jun 17;1(8651):1388–1389. doi: 10.1016/s0140-6736(89)92832-8. [DOI] [PubMed] [Google Scholar]
  31. Stone W. J., Graber S. E., Krantz S. B., Dessypris E. N., O'Neil V. L., Olsen N. J., Pincus T. P. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. Am J Med Sci. 1988 Sep;296(3):171–179. doi: 10.1097/00000441-198809000-00005. [DOI] [PubMed] [Google Scholar]
  32. Strickland I. D., Chaput de Saintonge D. M., Boulton F. E., Francis B., Roubikova J., Waters J. I. The therapeutic equivalence of oral and intravenous iron in renal dialysis patients. Clin Nephrol. 1977 Feb;7(2):55–57. [PubMed] [Google Scholar]
  33. Van Wyck D. B., Stivelman J. C., Ruiz J., Kirlin L. F., Katz M. A., Ogden D. A. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int. 1989 Feb;35(2):712–716. doi: 10.1038/ki.1989.43. [DOI] [PubMed] [Google Scholar]
  34. Watson A. J. Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol. 1989 Mar;9(1 Suppl 1):30–34. [PubMed] [Google Scholar]
  35. Winearls C. G. Erythropoietin. Nephrol Dial Transplant. 1989;4(5):323–326. doi: 10.1093/oxfordjournals.ndt.a091884. [DOI] [PubMed] [Google Scholar]
  36. Zehnder C. Erythropoietin treatment: influence of haemoglobin concentration on dialyser creatinine clearance in haemodialysed patients. Nephron. 1989;51(3):424–425. doi: 10.1159/000185339. [DOI] [PubMed] [Google Scholar]
  37. van Geet C., Hauglustaine D., Verresen L., Vanrusselt M., Vermylen J. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb Haemost. 1989 Feb 28;61(1):117–121. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES